Association of parental dementia with cognitive and brain MRI measures in middle-aged adults

Objectives: Studies of autosomal dominant Alzheimer disease (AD) have shown structural and cognitive changes in mutation carriers decades prior to clinical disease. Whether such changes are detectable in offspring of persons with sporadic dementia remains unknown. We related prospectively verified parental dementia to brain MRI and cognitive testing in the offspring, within a 2-generational community-based cohort. Methods: A total of 717 Framingham offspring (mean age: 59 ± 8 years) were studied. In multivariate analyses, we compared offspring with and without verified parental dementia (and AD) for 1) performance on tests of memory, abstract reasoning, and cognitive flexibility, and 2) volumetric brain MRI measures of total cerebral brain volume (TCBV), hippocampal volume (HV), and white matter hyperintensity volume (WMHV), assessed cross-sectionally and longitudinally. Results: When testing the association of parental dementia and AD with baseline cognitive performance, we observed an interaction of parental dementia and AD with APOE ε4 status (p < 0.002). In APOE ε4 carriers only (n = 165), parental dementia was associated with poorer scores on tests of verbal memory (beta = −1.81 ± 0.53, p < 0.001) and visuospatial memory (beta = −1.73 ± 0.47, p < 0.001). These associations were stronger for parental AD (beta = −1.97 ± 0.52, p < 0.001, beta = −1.95 ± 0.48, p < 0.001), equivalent to 14–16 years of brain aging. Among APOE ε4 carriers, offspring of participants with dementia were also more likely to show an annual decline in TCBV in the top quartile (odds ratio = 4.67 [1.26–17.30], p = 0.02). Regardless of APOE ε4 status, participants with parental dementia were more likely to be in the highest quartile of decline in executive function test scores (odds ratio = 1.61 [1.02–2.53], p = 0.04). Conclusions: Among middle-aged carriers of the APOE ε4 allele, parental dementia and Alzheimer disease were associated with poorer verbal and visuospatial memory and a higher rate of global brain atrophy.

[1]  Y. Agid,et al.  Apolipoprotein E ϵ4 Allele and Familial Aggregation of Alzheimer Disease , 1998 .

[2]  J. H. Lee,et al.  Genetic influences on memory performance in familial Alzheimer disease , 2004, Neurology.

[3]  R. D'Agostino,et al.  New Norms for a New Generation: Cognitive Performance in the Framingham Offspring Cohort , 2004, Experimental aging research.

[4]  Jean-François Dartigues,et al.  The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. , 2005, Brain : a journal of neurology.

[5]  Ronald C. Petersen,et al.  Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease , 2009, Alzheimer's & Dementia.

[6]  M. Gearing,et al.  The CERAD experience, part VIII , 1995, Neurology.

[7]  D. Harvey,et al.  Measures of brain morphology and infarction in the framingham heart study: establishing what is normal , 2005, Neurobiology of Aging.

[8]  P. Rothwell,et al.  Sex Differences in Heritability of Ischemic Stroke: A Systematic Review and Meta-Analysis , 2008, Stroke.

[9]  Laura Fratiglioni,et al.  APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. , 2004, Archives of neurology.

[10]  C. Jack,et al.  Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI , 2005, Neurology.

[11]  R B D'Agostino,et al.  Probability of stroke: a risk profile from the Framingham Study. , 1991, Stroke.

[12]  B. Caffo,et al.  Familial risk for Alzheimer's disease alters fMRI activation patterns. , 2006, Brain : a journal of neurology.

[13]  W. Kannel,et al.  Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. , 1987, Preventive medicine.

[14]  R. Barker,et al.  Neurodegeneration: a failure of neuroregeneration? , 2001, The Lancet.

[15]  Winnie S. Liang,et al.  GAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers , 2007, Neuron.

[16]  Y. Agid,et al.  Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease. , 1998, Archives of neurology.

[17]  R. O'Hara,et al.  Cognitive changes in young-old adults: effect of family history of dementia. , 1995, Journal of clinical and experimental neuropsychology.

[18]  Winnie S. Liang,et al.  GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. , 2007, Neuron.

[19]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[20]  R. Hu.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) , 2003 .

[21]  L. Bäckman,et al.  Cognitive deficits in preclinical Alzheimer's disease , 2003, Acta neurologica Scandinavica. Supplementum.

[22]  Nick C Fox,et al.  Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study , 2006, The Lancet Neurology.

[23]  M N Rossor,et al.  Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. , 1998, Brain : a journal of neurology.

[24]  B Johansson,et al.  Substantial genetic influence on cognitive abilities in twins 80 or more years old. , 1997, Science.

[25]  R. Green,et al.  Risk of dementia among white and African American relatives of patients with Alzheimer disease. , 2002, JAMA.

[26]  G J Blauw,et al.  Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  Charles DeCarli,et al.  Quantitative genetic modeling of regional brain volumes and cognitive performance in older male twins , 2002, Biological Psychology.

[28]  R. Swerdlow.  PET sheds light on Alzheimer's disease genetic risk , 2007, Proceedings of the National Academy of Sciences.

[29]  K. Davis,et al.  Patterns of risk in first-degree relatives of patients with Alzheimer's disease. , 1994, Archives of general psychiatry.

[30]  M. Barquero,et al.  Variability of age at onset in siblings with familial Alzheimer disease. , 2007, Archives of neurology.

[31]  John X. Morris,et al.  Increased risk of dementia in mothers of Alzheimer's disease cases , 1996, Neurology.

[32]  M. Postel-Vinay.  Growth hormone- and prolactin-binding proteins: soluble forms of receptors. , 1996, Hormone research.

[33]  Roberta F. White,et al.  The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. , 2000, Archives of neurology.

[34]  Charles DeCarli,et al.  Stroke Risk Profile Predicts White Matter Hyperintensity Volume: The Framingham Study , 2004, Stroke.

[35]  Sterling C. Johnson,et al.  Effect of parental family history of Alzheimer's disease on serial position profiles , 2008, Alzheimer's & Dementia.

[36]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[37]  Rachel L. Mistur,et al.  Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism , 2007, Proceedings of the National Academy of Sciences.

[38]  J. Haines,et al.  Apolipoprotein E4 allele and Alzheimer disease: Examination of Allelic association and effect on age at onset in both early‐and late‐onset cases , 1995, Genetic epidemiology.

[39]  Sudha Seshadri,et al.  Association of plasma total homocysteine levels with subclinical brain injury: cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. , 2008, Archives of neurology.

[40]  C. DeCarli,et al.  Brain Behavior Relationships Among African Americans, Whites, and Hispanics , 2008, Alzheimer disease and associated disorders.

[41]  A. Hofman,et al.  Genetic transmission of Alzheimer's disease among families in a Dutch population based study. , 1993, Journal of medical genetics.

[42]  V. Pankratz,et al.  Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease , 2009, Nature Genetics.